RHHB.F Stock Overview
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 5/6 |
Roche Holding AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF 288.23 |
52 Week High | CHF 368.43 |
52 Week Low | CHF 243.42 |
Beta | 0.15 |
11 Month Change | -17.88% |
3 Month Change | -19.49% |
1 Year Change | -0.27% |
33 Year Change | -30.04% |
5 Year Change | -5.19% |
Change since IPO | 130.59% |
Recent News & Updates
Recent updates
Shareholder Returns
RHHB.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -6.5% | -1.4% | 0.3% |
1Y | -0.3% | 10.8% | 31.1% |
Return vs Industry: RHHB.F underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: RHHB.F underperformed the US Market which returned 31.1% over the past year.
Price Volatility
RHHB.F volatility | |
---|---|
RHHB.F Average Weekly Movement | 7.3% |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 15.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RHHB.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RHHB.F's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1896 | 103,605 | Thomas Schinecker | www.roche.com |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas.
Roche Holding AG Fundamentals Summary
RHHB.F fundamental statistics | |
---|---|
Market cap | US$228.42b |
Earnings (TTM) | US$11.88b |
Revenue (TTM) | US$67.75b |
19.1x
P/E Ratio3.3x
P/S RatioIs RHHB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RHHB.F income statement (TTM) | |
---|---|
Revenue | CHF 60.58b |
Cost of Revenue | CHF 15.43b |
Gross Profit | CHF 45.16b |
Other Expenses | CHF 34.54b |
Earnings | CHF 10.62b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 13.33 |
Gross Margin | 74.54% |
Net Profit Margin | 17.53% |
Debt/Equity Ratio | 104.8% |
How did RHHB.F perform over the long term?
See historical performance and comparison